CAPTRUST Financial Advisors
TCRT icon

CAPTRUST Financial Advisors’s Alaunos Therapeutics TCRT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45
Closed -$8K – 3839
2022
Q2 		$8K Hold
45
– – ﹤0.01% 3882
2022
Q1 		$4K Hold
45
– – ﹤0.01% 4276
2021
Q4 		$7K Sell
45
-7
-13% -$1.54K ﹤0.01% 3927
2021
Q3 		$14K Buy
52
+7
+16% +$2.14K ﹤0.01% 3410
2021
Q2 		$18K Sell
45
-5
-10% -$2.33K ﹤0.01% 3187
2021
Q1 		$27K Buy
+50
New +$31.1K ﹤0.01% 2820
2019
Q4 		– Sell
-18
Closed -$11K – 1719
2019
Q3 		$11K Buy
+18
New +$14.3K ﹤0.01% 1477

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CAPTRUST Financial Advisors's TCRT Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2022, closing a stake of 45 shares — an estimated $8K sold.

CAPTRUST Financial Advisors first reported a position in TCRT in Q3 2019 and held it in 7 quarters. The position peaked at $27K in Q1 2021. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Alaunos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 45 Alaunos Therapeutics shares in Q3 2022, an estimated $8K.
  • CAPTRUST Financial Advisors first reported a position in Alaunos Therapeutics in Q3 2019 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Alaunos Therapeutics position peaked at $27K in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.